Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV

Douglas Dieterich, Mark Nelson, Vicente Soriano, Keikawus Arastéh, Josep M. Guardiola, Jürgen K. Rockstroh, Sanjay Bhagani, Montserrat Laguno, Cristina Tural, Patrick Ingiliz, Mamta K. Jain, Jerry O. Stern, Montserrat Manero, Richard Vinisko, Jens Kort

Research output: Contribution to journalArticleResearchpeer-review

10 Citations (Scopus)

Abstract

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. Objective: Faldaprevir is a potent, once-daily hepatitis C virus (HCV) NS3/4A protease inhibitor. STARTVerso4 assessed the efficacy and safety of faldaprevir and response-guided pegylated interferon α-2a/ribavirin (PegIFN/RBV) in individuals with HCV/HIV co-infection. Design: A phase 3 open-label study (NCT01399619). Methods: Individuals (N = 308) co-infected with HCV genotype 1 (treatment-naive or prior interferon relapsers) and HIV [96% on antiretroviral therapy (ART)] received faldaprevir 120 mg (N = 123) or 240 mg (N = 185) and PegIFN/RBV. Those receiving a protease inhibitor or efavirenz ART were assigned to faldaprevir 120 or 240 mg, respectively. Individuals achieving early treatment success (ETS; HCV RNA <25 IU/ml at week 4 and undetectable at week 8) were randomized to 24 or 48 weeks of PegIFN/RBV. The primary endpoint was sustained virologic response 12 weeks after treatment (SVR12). Results: SVR12 was achieved in 221 (72%) individuals, and the rates were comparable across faldaprevir doses. ETS was achieved in 80%, and of these 86% achieved SVR12, with comparable rates with 24 and 48 weeks of PegIFN/RBV (87 and 94%, respectively). In multivariate analysis, age below 40 years, IL28B CC genotype, and baseline HCV RNA below 800 000 IU/ml were associated with SVR12 (P = 0.027, P < 0.0001, and P = 0.0002, respectively), whereas treatment (ART regimen and faldaprevir dose), liver cirrhosis, and genotype 1 subtype were not. The safety profile was comparable to that of faldaprevir in HCV-monoinfected individuals. Conclusions: High SVR12 rates were achieved with faldaprevir and PegIFN/RBV in HIV/HCV co-infected individuals, regardless of faldaprevir dose and background ART, HCV genotype 1 subtype, or cirrhosis status. SVR rates mirrored those obtained with similar regimens in HCV monoinfected individuals.
Original languageEnglish
Pages (from-to)571-581
JournalAIDS
Volume29
Issue number5
DOIs
Publication statusPublished - 13 Mar 2015

Keywords

  • faldaprevir
  • hepatitis C virus genotype 1
  • HIV
  • NS3/4A protease inhibitor
  • SVR12

Fingerprint Dive into the research topics of 'Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV'. Together they form a unique fingerprint.

  • Cite this

    Dieterich, D., Nelson, M., Soriano, V., Arastéh, K., Guardiola, J. M., Rockstroh, J. K., Bhagani, S., Laguno, M., Tural, C., Ingiliz, P., Jain, M. K., Stern, J. O., Manero, M., Vinisko, R., & Kort, J. (2015). Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV. AIDS, 29(5), 571-581. https://doi.org/10.1097/QAD.0000000000000579